April 02, 2019
Daiichi Sankyo Company, Limited (hereafter, Daiichi Sankyo) has announced that it has entered into a global development and commercialization agreement with AstraZeneca for Daiichi Sankyo’s lead antibody drug conjugate (ADC), [fam-] trastuzumab deruxtecan (DS-8201), currently in pivotal development for multiple HER2 expressing cancers including breast and gastric cancer, and additional development in non-small cell lung and colorectal cancer.
Latham & Watkins LLP represents Daiichi Sankyo in the collaboration. The deal team was led by Silicon Valley partner Judith Hasko with Silicon Valley associates Gavin Liu and Peggy Ni. Advice was also provided on tax matters by San Francisco partner Kirt Switzer with associate Jessica Chen; on antitrust matters by Washington, D.C. partner Mandy Reeves and Brussels partner Hector Armengod; and on data privacy matters by London associate Frances Stocks Allen. Tokyo partner Nozomi Oda provided corporate advice on the transaction.